Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma Academic Article uri icon

Overview

MeSH Major

  • Benzimidazoles
  • Melanoma
  • Mitogen-Activated Protein Kinase Kinases
  • Mutation
  • Proto-Oncogene Proteins B-raf

abstract

  • Tumor regression was seen in three of five patients with BRAF-mutated, low pAKT melanomas; no responses were seen in the high pAKT cohort. These results provide rationale for co-targeting MEK and PI3K/AKT in patients with BRAF mutant melanoma whose tumors express high pAKT. However, the complexity of genetic changes in melanoma indicates that additional genetic information will be needed for optimal selection of patients likely to respond to MEK inhibitors.

publication date

  • April 15, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3932005

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-12-3476

PubMed ID

  • 23444215

Additional Document Info

start page

  • 2257

end page

  • 64

volume

  • 19

number

  • 8